Kindeva Drug Delivery presented cutting-edge advancements in pulmonary & nasal development and manufacturing at the Drug Delivery to the Lungs (DDL) conference on December 6-8, 2023. Across eight posters and podium presentations, we highlighted strategies for switching to green propellant formulations while preserving product performance, among a variety of other topics.
If you missed any of our presentations or would like a copy to reference, fill out the below form.
In Silico Modelling to Aid Product Development Strategy for Low Global Warming Potential MDIs — Neha Patel, Alex Richford
Understanding Fundamental Formulation Properties to Demonstrate the Feasibility of Reformulating a Salbutamol pMDI Containing the Low-GWP Propellant HFO1234ze(E) — Alex Slowey, Ben Myatt, Phil Cocks
Development and Optimisation of a Particle Sizing Methodology for Early Screening of DPI Carrier Based Formulations using Laser Diffraction — James McNeill, Jim Clay, Olivia Brittan
The Effect of Elastomer Type on Stem-Diaphragm Leakage from pMDIs filled with Propellant 152a — Howard Bleazard, Lee Hodges
Spray Pattern and Plume Geometry Measurements of Current and Low-GWP Propellants HFA152a and HFO1234ze(E) pMDIs With and Without Ethanol — Holly Dowdle, Ben Myatt
A Novel Mathematical Model to Predict the Particle Size Distribution of pMDI Aerosols — Hossain Chizari, H.K. Versteeg, W. Malalasekra, B. Gavtash
A Multi-Physics Theoretical and CFD Approach, To Predict Low-GWP pMDI Spray Characteristics, Inside USP-IP Geometry — Hossain Chizari, Barzin Gavtash
Do In Vitro Dissolution Rates Differ Between Drug Particles Generated From Solution-Based pMDIs Formulated With HFA134a, HFA152a and HFO1234ze(E) Propellants? — Hui Xin Ong, Nirmal Marasini, Lingzhe Rao, Daniel Duke, Damon Honnery, Stephen W. Stein, Benjamin Myatt, Phil Cocks & Paul Young
To see more pulmonary & nasal capabilities, click here.
Fields marked with an * are required.